Novo Nordisk : SELECT: des résultats qui justifient un changement de la prise en charge
>Confirmation de l’intérêt de Wegovy dans la protection cardiaque des obèses - Novo Nordisk est revenu, lors du congrès de l’AHA, sur les résultats cliniques de son essai nommé SELECT. Pour rappel, l’objectif de cet essai était de démontrer que la prise de Wegovy chez des patients souffrant d'obésité et d'une maladie cardiovasculaire sans antécédents de diabète améliorait la fonction cardio-vasculaire de cette population (n=17 604). Le critère primaire était un critèr...Novo-Nordisk is a global healthcare company engaged in the innovation of diabetes care. Co. also provides haemophilia care, growth hormone therapy and hormone replacement therapy. The Diabetes care business segment includes research, development, manufacturing and marketing of products within the areas of insulin, GLP-1 and related delivery systems, oral antidiabetic products (OAD) and obesity. The Biopharmaceuticals business segment includes research, development, manufacturing and marketing of products within the areas of haemophilia, growth hormone therapy, hormone replacement therapy, inflammation therapy and other therapy areas.
Oddo Securities provides securities brokerage and research services. The company offers equity, economic, and derivatives research and credit analysis services. It focuses on insurance, automotive, building materials, pharmaceuticals, telecommunications, information technology, and agri-food industries.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.